Randomized Trialhigh evidence
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.
Nature medicine·July 1, 2024·PMID 38858523
Why it mattersRetatrutide, a triple agonist, shows substantial liver fat reduction in MASLD, exceeding effects seen with other agents. This suggests a potential disease-modifying role, addressing both steatosis and cardiometabolic risk factors.

The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled